Sundia: BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent

BioDuro and Sundia, two pre-clinical China-US CROs, have merged to form one of the largest CRDMOs with operations in China and the US. As part of the deal, Advent, a Boston private equity investor, will lead a majority investment in Sundia. In early 2019, Advent acquired control of BioDuro, also via a majority investment. The new company, which will operate as BioDuro-Sundia, will offer drug discovery, development and manufacturing for both APIs and drug products. Bridgewest Capital was a co-investor in Sundia. Financial terms were not disclosed. More details....Share this with colleagues: